ScholarIQanswers from OpenAlex

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor

PaperCitations, authors & open-access status

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor have?

ScholarIQcitation count

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor has 830 citations in the OpenAlex counts ScholarIQ stores.

When was Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor published?

ScholarIQyear

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor has 1999 year in the ScholarIQ index.

What is the open-access status of Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor?

ScholarIQoa status

Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor has bronze oa status in the ScholarIQ index.

What is the DOI of Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor?

ScholarIQdoi

The DOI for Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor is on the source record.

What is the PMID of Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor?

ScholarIQpmid

The PMID for Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor is on the source record.

What is the OpenAlex record for Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor?

ScholarIQopenalex

The OpenAlex for Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial